1082 related articles for article (PubMed ID: 32856210)
1. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
2. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
3. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
[TBL] [Abstract][Full Text] [Related]
4. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
Suarez-Almazor ME; Pundole X; Abdel-Wahab N; Johnson DB; Gupta D; Glezerman I; Cooksley T; Anderson R; Blidner A; Choi J; Dougan M; Ginex P; Girotra M; Shannon VR; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6159-6173. PubMed ID: 32856212
[TBL] [Abstract][Full Text] [Related]
5. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
Choi J; Anderson R; Blidner A; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Lacouture ME
Support Care Cancer; 2020 Dec; 28(12):6119-6128. PubMed ID: 32856211
[TBL] [Abstract][Full Text] [Related]
6. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
8. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
9. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune complications of immunotherapy: pathophysiology and management.
Chan KK; Bass AR
BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
[TBL] [Abstract][Full Text] [Related]
13. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
14. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
19. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
[TBL] [Abstract][Full Text] [Related]
20. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors.
Townsend MJ; Benque IJ; Li M; Grover S
Aliment Pharmacol Ther; 2024 Jun; 59(11):1350-1365. PubMed ID: 38590108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
